DSpace Repository

RECENT PROGRESS IN TARGETED RADIOISOTOPE THERAPY (TRT) AT QST, JAPAN

Show simple item record

dc.contributor.author Higashi, Tatsuya
dc.date.accessioned 2020-12-03T10:11:57Z
dc.date.available 2020-12-03T10:11:57Z
dc.date.issued 2020
dc.identifier.uri http://nur.nu.edu.kz/handle/123456789/5175
dc.description.abstract Targeted Radioisotope Therapy (TRT) is known as a radiotherapy using cytotoxic radioisotopes which are administered orally or intravenously in a patient and accumulate in a targeted organ or a tumor. Recently, QST started a joint clinical trial of our newly-developed TRT agent, Cu-64 ATSM , a radionuclide which emits β-rays, with National Cancer Center Hospital for the treatment of brain tumors. This is the first time in Japan to have a clinical study of Japan-made TRT agent. Although only beta emitters had been utilized, an alpha emitter, Radium-223 (Ra-223), was introduced in this field recently. The treatment number of Ra-223 therapy is increasing rapidly world-wide and also in Japan. Alpha emitters are known with its high LTE (linear transfer effect), high RBE (relative biological effect) and their short ray range in the body. Because of these characteristics, several alpha emitters are expected to be promising TRT agents. In this session, I would like to talk about Actinium-225 (Ac-225) and Astatine-211(At-211) and their radiolabeled agents. In Japan, several At-211radiolabeled agents have been developed and showed their strong therapeutic effects. In our QST, Ac-225 was synthesized by cyclotron for the first time in Japan, recently. In TRT, treatment eligibility can be confirmed through molecular imaging with diagnostic RI on the same (or similar) chemical structure of a radiopharmaceutical replacing therapeutic RI. “Theranostics” is a new term which means the combination of therapy and diagnosis and has become a new field of medicine. In QST, this “theranostics” research is also conducted actively. For the development of TRT, we have to overcome several technological barriers and social obstacles. We will show you some of our social activities. en_US
dc.language.iso en en_US
dc.publisher International conference "MODERN PERSPECTIVES FOR BIOMEDICAL SCIENCES: FROM BENCH TO BEDSIDE”; National Laboratory Astana en_US
dc.rights Attribution-NonCommercial-ShareAlike 3.0 United States *
dc.rights.uri http://creativecommons.org/licenses/by-nc-sa/3.0/us/ *
dc.subject Research Subject Categories::MEDICINE en_US
dc.subject TRT en_US
dc.subject Targeted Radioisotope Therapy en_US
dc.title RECENT PROGRESS IN TARGETED RADIOISOTOPE THERAPY (TRT) AT QST, JAPAN en_US
dc.type Abstract en_US
workflow.import.source science


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 3.0 United States Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 3.0 United States

Video Guide

Submission guideSubmission guide

Submit your materials for publication to

NU Repository Drive

Browse

My Account

Statistics